Abstract:Migraine is a common brain condition characterised by disabling attacks of headache with sensory sensitivities. Despite increasing understanding of migraine neurobiology and the impacts of this on therapeutic developments, there remains a need for treatment options for patients underserved by currently available therapies. The first specific drugs developed to treat migraine acutely, the serotonin-5-hydroxytryptamine [5-HT 1B/1D ] receptor agonists (triptans), seem to require headache onset in order to have an effect, while early treatment during mild pain before headache escalation improves short-term and long-term outcomes. Some patients find treating in the early window once headache has started but not escalated difficult, and migraine can arise from sleep or in the early hours of the morning, making prompt treatment after pain onset challenging. Triptans may be deemed unsuitable for use in patients with vascular disease and in those of older age and may not be effective in a proportion of patients. Headache is also increasingly recognised as being just one of the many facets of the migraine attack, and for some patients it is not the most disabling symptom. In many patients, painless symptoms can start prior to headache onset and can reliably warn of impending headache. There is, therefore, a need to identify therapeutic targets and agents that may be used as early as possible in the course of the attack, to prevent headache onset before it starts, and to reduce both headache and non-headache related attack burden. Early small studies using domperidone, naratriptan and dihydroergotamine have suggested that this approach could be useful; these studies were methodologically less rigorous than modern day treatment studies, of small sample size, and have not since been replicated. The emergence of novel targeted migraine treatments more recently, specifically calcitonin gene-related peptide (CGRP) receptor antagonists (gepants), has reignited interest in this strategy, with encouraging results. This review summarises historical and emerging data in this area, supporting use of the premonitory phase as an opportunity to intervene as early as possible in migraine to prevent attack-related morbidity.

Side effects associated with current and prospective antimigraine pharmacotherapies

Migraine: Pathophysiology, Pharmacology, Treatment and Future Trends

Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second‐Generation Gepants, and Cardiovascular Risk

Cardiovascular Disease and Migraine: Are the New Treatments Safe?

The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review

New Generation Gepants: Migraine Acute and Preventive Medications

Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials

Migraine Treatment: Towards New Pharmacological Targets

Gepants for the treatment of migraine

Drug-related side effects and adverse reactions in the treatment of migraine: a bibliometric and visual analysis

Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations

Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

New Oral Drugs for Migraine

The pathophysiological and pharmacological basis of current drug treatment of migraine headache

Advances in Pharmaceutic Managements of Migraine

Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy

Novel Therapeutic Targets for Migraine

Potential benefits and possible risks of CGRP-targeted multitherapy in migraine

Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies

Preventive and abortive treatment of migraine with traditional drugs. The state of the art

Future targets for migraine treatment beyond CGRP